MCK Share Price | McKesson Corp. Stock Analysis & Recommendation

Q: What does McKesson Corp. do?

Overview:McKesson Corporation is a healthcare supply chain management solution provider operating in the retailing industry, with a market cap classified as large cap.Financial Snapshot:Most recent Net Sales: 90,823 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 1,306 Million (Quarterly Results - Mar 2025) Market cap: USD 179,003.16 Million (Large Cap)Key Metrics:P/E: 56.00 Dividend Yield: 21.40% Debt Equity: 0.10 Return on Equity: -151.11% Price to Book: -86.31 Contact Details:Address: 6555 State Highway 161, IRVING TX: 75039-2402 Tel: 1 972 4464800 Website: http://www.mckesson.com

Q: Who are in the management team of McKesson Corp.?

As of March 2022, the management team of McKesson Corp. includes the following individuals:- Mr. Edward Mueller, who serves as the Independent Chairman of the Board.- Mr. Brian Tyler, who is the Chief Executive Officer and a Director.- Mr. Dominic Caruso, who is an Independent Director.- Dr. N. Anthony Coles, who is also an Independent Director.- Ms. Christine Jacobs, serving as an Independent Director.- Mr. Donald Knauss, who is an Independent Director.- Ms. Marie Knowles, who is another Independent Director. This team plays a crucial role in guiding the company's strategic direction and governance.

Q: Is McKesson Corp. overvalued or undervalued?

As of 2 February 2021, the valuation grade for McKesson Corp. moved from attractive to risky, indicating a shift in its perceived investment quality. The company appears to be overvalued, given its high P/E ratio of 56 and an EV to EBITDA ratio of 36.93, which significantly exceeds those of its peers. For comparison, Boston Scientific Corp. has a P/E of 73.71 and an EV to EBITDA of 45.38, while Cencora, Inc. shows a more reasonable P/E of 40.09 and an EV to EBITDA of 19.45.Despite the overvaluation, McKesson has demonstrated strong stock performance, with a 1-year return of 34.89% compared to the S&P 500's 17.14%, and a remarkable 5-year return of 353.64% against the S&P 500's 96.61%. However, the negative price-to-book value of -84.94 and the negative return on equity suggest underlying financial challenges that could impact future performance.

Q: Is McKesson Corp. technically bullish or bearish?

As of 10 July 2025, the technical trend for McKesson Corp. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD remains bullish, indicating mixed signals. The daily moving averages are mildly bullish, suggesting some short-term strength. However, the weekly Bollinger Bands are bearish, and the KST is mildly bearish on both weekly and monthly time frames. Dow Theory shows no trend on the weekly and mildly bearish on the monthly.In terms of performance, McKesson has outperformed the S&P 500 year-to-date with a return of 21.09% compared to 12.22%, and over one year, it has returned 34.89% versus the S&P 500's 17.14%. Overall, the current stance is mildly bullish, but with caution due to the bearish indicators present in the weekly analysis.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

980.25 k

Shareholding (Dec 2025)

FII

25.11%

Held by 507 FIIs

DII

43.28%

Held by 46 DIIs

Promoter

0.01%

How big is McKesson Corp.?

22-Jun-2025

As of Jun 18, McKesson Corp. has a market capitalization of $179 billion, with net sales of $359 billion and a net profit of $3.48 billion over the latest four quarters.

View full answer

What does McKesson Corp. do?

22-Jun-2025

McKesson Corporation is a large-cap healthcare supply chain management provider, with recent net sales of $90.8 billion and a net profit of $1.3 billion. Key financial metrics include a P/E ratio of 56.00 and a dividend yield of 21.40%.

View full answer

Who are in the management team of McKesson Corp.?

22-Jun-2025

As of March 2022, McKesson Corp.'s management team includes Independent Chairman Edward Mueller, CEO Brian Tyler, and Independent Directors Dominic Caruso, N. Anthony Coles, Christine Jacobs, Donald Knauss, and Marie Knowles, who collectively guide the company's strategic direction and governance.

View full answer

Is McKesson Corp. overvalued or undervalued?

20-Sep-2025

As of February 2, 2021, McKesson Corp. is considered risky due to its high valuation metrics and negative financial indicators, despite strong stock performance over the past year and five years.

View full answer

Is McKesson Corp. technically bullish or bearish?

20-Sep-2025

As of July 10, 2025, McKesson Corp. shows a mildly bullish trend overall, despite mixed signals from technical indicators, with a year-to-date return of 21.09% compared to the S&P 500's 12.22%.

View full answer

Compare McKesson Corp. with Similar Stocks

Boston Scientific Corp.Cencora, Inc.Cardinal Health, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Risky - Negative Book Value

Mojo Parameters

Stock DNA

Industry

Retailing

Market cap

USD 230,613 Million (Large Cap)

P/E

57.00

Industry P/E

Dividend Yield

18.54%

Debt Equity

-2.92

Return on Equity

-313.91%

Price to Book

-177.67

Revenue and Profits:

Net Sales:

106,158 Million

(Quarterly Results - Dec 2025)

Net Profit:

1,250 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

9.29%

6 Months

28.36%

1 Year

33.89%

2 Years

67.23%

3 Years

161.04%

4 Years

196.22%

5 Years

371.22%

McKesson Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

10.86%

EBIT Growth (5y)

7.74%

EBIT to Interest (avg)

16.14

Debt to EBITDA (avg)

0.25

Net Debt to Equity (avg)

0.10

Sales to Capital Employed (avg)

77.18

Tax Ratio

20.14%

Dividend Payout Ratio

10.69%

Pledged Shares

Institutional Holding

92.15%

ROCE (avg)

377.27%

ROE (avg)

72.81%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

-177.67

EV to EBIT

45.46

EV to EBITDA

40.14

EV to Capital Employed

94.06

EV to Sales

0.59

PEG Ratio

2.12

Dividend Yield

18.54%

ROCE (Latest)

206.90%

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

Bullish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 188 Schemes (31.6%)

Foreign Institutions

Held by 507 Foreign Institutions (25.11%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 11.40% vs 17.80% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 34.70% vs 47.30% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "106,158.00",
          "val2": "95,294.00",
          "chgp": "11.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,828.00",
          "val2": "1,440.00",
          "chgp": "26.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "63.00",
          "val2": "67.00",
          "chgp": "-5.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-21.00",
          "val2": "-63.00",
          "chgp": "66.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,250.00",
          "val2": "928.00",
          "chgp": "34.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "15.40%",
          "val2": "13.50%",
          "chgp": "0.19%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 16.22% vs 11.65% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 10.16% vs -15.17% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "359,051.00",
          "val2": "308,951.00",
          "chgp": "16.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "5,008.00",
          "val2": "4,562.00",
          "chgp": "9.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "256.00",
          "val2": "243.00",
          "chgp": "5.35%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "99.00",
          "val2": "-51.00",
          "chgp": "294.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "3,481.00",
          "val2": "3,160.00",
          "chgp": "10.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "12.20%",
          "val2": "12.70%",
          "chgp": "-0.05%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

106,158.00

95,294.00

11.40%

Operating Profit (PBDIT) excl Other Income

1,828.00

1,440.00

26.94%

Interest

63.00

67.00

-5.97%

Exceptional Items

-21.00

-63.00

66.67%

Consolidate Net Profit

1,250.00

928.00

34.70%

Operating Profit Margin (Excl OI)

15.40%

13.50%

0.19%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 11.40% vs 17.80% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 34.70% vs 47.30% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

359,051.00

308,951.00

16.22%

Operating Profit (PBDIT) excl Other Income

5,008.00

4,562.00

9.78%

Interest

256.00

243.00

5.35%

Exceptional Items

99.00

-51.00

294.12%

Consolidate Net Profit

3,481.00

3,160.00

10.16%

Operating Profit Margin (Excl OI)

12.20%

12.70%

-0.05%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2025 is 16.22% vs 11.65% in Mar 2024

Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 10.16% vs -15.17% in Mar 2024

All Annual Results

Company CV

About McKesson Corp.

McKesson Corp.

Retailing

McKesson Corporation is a healthcare supply chain management solution, retail pharmacy, community oncology and specialty care, and healthcare information technology company. The Company provides medicines, medical products and healthcare services by partnering with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare. It operates through three segments: United States Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions and Medical-Surgical Solutions. The United States Pharmaceutical and Specialty Solutions segment distributes pharmaceutical and other healthcare related products and provides pharmaceutical solutions to life sciences companies. European Pharmaceutical Solutions segment provides distribution and services to wholesale, institutional and retail customers. Medical-Surgical Solutions segment distributes medical-surgical supplies and provides logistics and other services to healthcare providers.

Company Coordinates

Company Details

6555 State Highway 161 , IRVING TX : 75039-2402

Tel: 1 972 4464800

http://www.mckesson.com

Registrar Details